SERVIER
13.6.2019 09:02:04 CEST | Business Wire | Press release
Servier today announced that the European Commission (EC) has approved the conversion of the conditional approval of PIXUVRI® (pixantrone) into a standard marketing authorization as a single agent for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma.
“There are limited treatment options for multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma,” said Prof Pier Luigi Zinzani from the University of Bologna Institute of Hematology and Medical Oncology in Bologna, Italy. “PIXUVRI has demonstrated efficacy in late stage disease and the EC approval confirms PIXUVRI as a treatment option for these patients.”
The EC approval is based on data from the global clinical development of PIXUVRI.
The pivotal study, PIX301 was an open-label, randomized, Phase III study comparing PIXUVRI monotherapy with physician's choice of treatment in 140 patients with relapsed or refractory aggressive non-Hodgkin lymphoma, 50% of whom had been previously treated with rituximab. PIXUVRI was shown to be beneficial in these patients: 20% of patients responded completely to PIXUVRI compared with 5.7% of patients receiving other agents (p=0.021).1,2
To satisfy requirements of the conditional authorization, a further Phase III clinical study, PIX306, was completed to provide additional efficacy data to confirm the benefit of PIXUVRI in patients that had received prior treatment regimens containing rituximab. In the study PIX306, all patients were previously treated with rituximab. While the superiority of PIXUVRI with rituximab compared to gemcitabine with rituximab was not met, both progression-free survival and overall survival results in patients with ≥ 2 prior treatment lines were similar, when indirectly compared to the PIXUVRI treated population in the pivotal study PIX301.2,3
“At Servier, we work diligently to develop and deliver medicines that address critical unmet medical needs in diseases such as multiply relapsed or refractory aggressive non-Hodgkin lymphoma,” said Patrick Therasse, Head of Servier Research and Development Oncology. “PIXUVRI has been benefitting patients since its conditional approval in 2012 but today’s decision brings reassurance to patients and clinicians that this medicine remains a relevant treatment option in this indication.”
The most common side effects with PIXUVRI are neutropenia, leukopenia, lymphopenia, anemia, thrombocytopenia, nausea, vomiting, skin discolouration, alopecia, chromaturia and asthenia.1
#ENDS#
About non-Hodgkin lymphoma (NHL)
NHL is a blood cancer that affects the lymphatic system, which is defined as a network of vessels and glands that run throughout the body.4 The lymphatic system is a key component of the immune system, as it plays a role in destroying old or abnormal cells and fighting bacteria and other infections.5
NHL can occur in different parts of the body from the lymph nodes in the neck to the liver or spleen, but also in other organs such as the stomach, small bowel, bones, brain, testicles or skin.6 Around 168,000 new cases of NHL are diagnosed in the United States and Europe every year.
About PIXUVRI (pixantrone)
PIXUVRI is indicated in the European Union as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma.7 PIXUVRI is a cytotoxic medicine that works by interfering with the DNA within cells and preventing them from making more copies of DNA. This means that the cancer cells cannot divide and eventually die.8
PIXUVRI is mentioned in the ESMO guidelines as an anthracycline-like drug with reduced cardiotoxicity, which demonstrated some efficacy in heavily treated patients.9
More detail is available in the summary of the European public assessment report (EPAR) on the EMA website at www.ema.europa.eu .
Servier commercializes PIXUVRI under a license from CTI BioPharma.
About Servier
Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.2 billion euros in 2018, Servier employs 22,000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generics) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.
Becoming a key player in oncology is part of Servier’s long-term strategy. Currently, there are twelve molecular entities in clinical development in this area, targeting gastro-intestinal and lung cancers and other solid tumors, as well as different types of leukemia and lymphomas. This portfolio of innovative cancer treatments is being developed with partners worldwide, and covers different cancer hallmarks and modalities, including cytotoxics, proapoptotics, immune targeted therapies, to deliver life-changing medicines to patients.
More information: www.servier.com
Find us on Social Media:
1 European Medicines Agency. Pixuvri SmPC. Available at: https://www.ema.europa.eu/en/documents/product-information/pixuvri-epar-product-information_en.pdf [last accessed May 2019].
2 Pettengell, R. et al. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncol 2012; 13: 696–706
3 Salles, G.A, et al. Results of a phase 3 randomized multicenter study comparing pixantrone + rituximab with gemcitabine + rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation. American Society Hematology annual congress 2018. P4189.
4 NHS Conditions webpage. NHL Cancer. Available at http://www.nhs.uk/Conditions/non-hodgkins-lymphoma/Pages/Definition.aspx [last accessed May 2019].
5 Cancer Research UK. Lymphatic System. Available at http://www.cancerresearchuk.org/about-cancer/what-is-cancer/body-systems-and-cancer/the-lymphatic-system-and-cancer [last accessed May 2019].
6 Cancer Research UK. What is NHL cancer. Available at http://www.cancerresearchuk.org/about-cancer/type/non-hodgkins-lymphoma/about/what-is-lymphoma [last accessed May 2019].
7 Pixuvri Summary of Product Characteristics, Available at: https://www.medicines.org.uk/emc/medicine/29829 [last accessed May 2019].
8 European Medicines Agency. Summary of the European public assessment report (EPAR) for Pixuvri. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/pixuvri [last accessed May 2019].
9 Tilly H et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology (2015). Volume 26 (suppl 5); v116-v125. Available at http://www.esmo.org/Guidelines/Haematological-Malignancies/Diffuse-Large-B-Cell-Lymphoma [last accessed May 2019].
View source version on businesswire.com: https://www.businesswire.com/news/home/20190613005025/en/
Contact:
Servier Media Relations Sonia MARQUES: media@servier.com Tel.: +33 (0)1 55 72 40 21 / + 33 (0)7 84 28 76 13
Jean-Clément VERGEAU: media@servier.com Tel.: +33 (0)1 55 72 46 16 / +33 (0)6 79 56 75 96
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NetApp Data Platform Powers Data Operations for Super Bowl LX27.1.2026 14:00:00 CET | Press release
Intelligent Data Infrastructure Elevates the Fan Experience at Levi’s® Stadium NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced that it is powering data operations for Super Bowl LX. As the Official Intelligent Data Infrastructure Partner of the San Francisco 49ers and the National Football League (NFL), NetApp provides the enterprise-grade data platform that powers the digital and physical experiences for football fans, whether watching the game from Levi’s® Stadium or from their couch on the other side of the world. “The world runs on data, even in an industry as physical as sports,” said Gabie Boko, Chief Marketing Officer at NetApp. “Optimizing data for innovation isn’t just about where the data lives, but also about how it moves. There is no place where that will be on display more clearly than Levi’s® Stadium during the Super Bowl. While the stadium is not a traditional data center, during a game, it transforms into an interactive data center b
REVEAL GENOMICS Aligns Founder Leadership With Priorities to Support Long-term Growth, Scientific Excellence, and Global Partnerships27.1.2026 13:43:00 CET | Press release
The company appoints Joel Parker, Ph.D., as Chief Scientific Officer; Ana Vivancos, Ph.D., as Director of NGS and Genomic Technologies; and Aleix Prat, M.D., Ph.D., as Chairman of the Board of Directors.Leadership roles are assumed by the company’s co-founders, who strengthen governance and alignment across scientific, clinical, and strategic priorities.The strengthened leadership framework supports global scientific progress and clinical adoption of the genomic assays of REVEAL GENOMICS. REVEAL GENOMICS, a Barcelona-based biotechnology company that advances precision oncology through biomarker innovation, today announced a strengthened leadership framework with several senior appointments. These appointments underscore the company’s commitment to scientific excellence, technological rigor, and clinical impact, and they seek to support the continued development, validation, and global adoption of the company’s genomic assays. This press release features multimedia. View the full releas
Bial Achieves Key Milestone in Phase 2b ACTIVATE Study of BIA 28-6156 in GBA1-Associated Parkinson’s Disease27.1.2026 12:00:00 CET | Press release
75% of patients have completed the Week 78 Last Study VisitTopline results expected in mid-2026 Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced that 75% of patients currently enrolled in its ongoing Phase 2b clinical study ACTIVATE (ClinicalTrials.gov identifier: NCT05819359) have completed the double-blind treatment period through week 78. This operational milestone represents a significant step toward the completion of the ACTIVATE study, which is evaluating the efficacy, safety, tolerability, pharmacodynamics, and pharmacokinetics of BIA 28-6156 in patients with Parkinson’s disease (PD) who have a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene (GBA-PD). The date of the Last Patient, Last Visit (LPLV) is anticipated in April 2026, with topline results on track to be released in mid-2026. “We look forward to presenting data from our Phase 2b study. BIA 28-6156 is the leading asset in GBA-PD, and clinical out
Libraesva and Cyber Guru Announce Strategic Combination to Create a Leading European Human-Centric Cybersecurity Provider27.1.2026 11:00:00 CET | Press release
The combination of two Italian cybersecurity leaders with strong international footprints creates a unique European player delivering an integrated portfolio of Email Security and Security Awareness Training to reduce human cyber risk end-to-end. Cyber Guru and Libraesva today announced a strategic combination that brings together two highly complementary Italian cybersecurity companies to form a new European leader in human-centric cyber protection. The combined group will offer organisations an integrated approach to defending against email-based threats, social engineering, and human-targeted attacks, integrating advanced technology with behavioural resilience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127531600/en/ Cyber threats are evolving rapidly, with attackers focusing less on infrastructure and more on the weak link in security – human behaviour. Phishing, business email compromise, smishing, QR-code attack
Europe’s First Meteorological Infrared Sounder Reveals the Atmosphere in 3D27.1.2026 10:30:00 CET | Press release
The first images from Europe’s pioneering meteorological infrared sounder were unveiled today at the EU Space Conference in Brussels, marking a major advance in the ability to monitor how the atmosphere evolves before and during severe weather. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127490399/en/ Full Earth disc image from the MTG-S Infrared Sounder showing a surface-temperature-sensitive channel, captured between 12:45 and 15:30 UTC on 15 November 2025. The image distinguishes land and sea surface temperatures as well as cloud-top temperatures, highlighting cloud structures and weather systems. Hot desert regions appear in red, while cold cloud tops are shown in blue. © Image: Data acquired on 15 November 2025 and processed by industrial partners Thales and OHB under the supervision of EUMETSAT and ESA. Visual produced by EUMETSAT. The images were captured by the Infrared Sounder (IRS) flying aboard Meteosat Thir
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom